Short Interest in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Decreases By 97.0%

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the recipient of a large decline in short interest during the month of July. As of July 31st, there was short interest totaling 16,980 shares, a decline of 97.0% from the July 15th total of 569,675 shares. Based on an average daily volume of 555,531 shares, the short-interest ratio is currently 0.0 days. Approximately 1.7% of the company’s shares are short sold.

Insider Transactions at Bluejay Diagnostics

In other news, major shareholder Financial Lp Hrt acquired 64,047 shares of the firm’s stock in a transaction on Thursday, July 9th. The shares were purchased at an average cost of $1.51 per share, for a total transaction of $96,710.97. Following the transaction, the insider owned 126,993 shares of the company’s stock, valued at approximately $191,759.43. This represents a 101.75% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics as of its most recent SEC filing. Hedge funds and other institutional investors own 18.47% of the company’s stock.

Bluejay Diagnostics Stock Up 8.4%

BJDX stock traded up $0.08 during midday trading on Tuesday, reaching $1.07. The company’s stock had a trading volume of 748,595 shares, compared to its average volume of 7,375,797. The business’s 50-day simple moving average is $2.31 and its 200-day simple moving average is $2.24. Bluejay Diagnostics has a 52 week low of $0.83 and a 52 week high of $16.68. The stock has a market cap of $1.10 million, a PE ratio of -0.09 and a beta of 0.89.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Wall Street Zen raised Bluejay Diagnostics to a “sell” rating in a research note on Saturday, July 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.